Find your next paid study

Children's Hospital of PhiladelphiaNCT07549646

~$75 – $2,000

Actual pay is set by the research site.

Metastatic Castration-resistant Prostate Cancer

A Phase III, Multicentre, Randomised Controlled Study to Evaluate the Efficacy and Safety of AZD2265 (FPI-2265) ²²⁵Ac-PSMA-I&T Compared With Standard of Care in Patients With PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)

The intention of the study is to demonstrate superiority of AZD2265 relative to standard of care treatments by assessment of radiographic progression-free surv…

~$50 – $2,250

Actual pay is set by the research site.

AstraZenecaNCT07611110

Phase 2

Strategy for Improving Stroke Treatment Response (SISTER) Trial

SISTER is a Phase-II, prospective, randomized, placebo-controlled, blinded, dose finding trial that aims to determine the safety and preliminary efficacy of TS…

Ischemic Stroke

Translational Sciences, Inc.NCT05948566

~$75 – $2,800

Actual pay is set by the research site.

Vanishing White Matter Disease

A Phase 1b/2 Open-label Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy Following Fosigotifator Administration in Adult and Pediatric Subjects With Vanishing White Matter Disease

Fosigotifator is an investigational drug being researched for the treatment of Vanishing White Matter disease in adult, pediatric and infant participants. This…

Calico Life Sciences LLCNCT05757141

~$150 – $4,200

Actual pay is set by the research site.

HNSCC,Larynx, Pharynx and Oral CavitySquamous Cell CarcinomaHead and Neck Cancer+1 more

Phase I Open-Label Study Evaluating the Safety and Feasibility of Panitumumab-IRDye800 and [18F]NOTA-ABY-030 for Targeted Dual-Modality Imaging (TDMI) in Head and Neck Squamous Cell Carcinoma

The goal of this clinical trial is to learn whether using two imaging agents-Panitumumab-IRDye800 (Pan800) and\[18F\]NOTA-ABY-030-is safe and feasible for help…

Vanderbilt-Ingram Cancer CenterNCT07741643

~$150 – $3,000

Actual pay is set by the research site.

Observational

Tumor Treating Fields: Pilot Study of Adjuvant Treatment for Brainstem Gliomas

This clinical trial tests the safety and side effects of tumor treating fields in treating patients with gliomas located in the brainstem. Optune is a wearable…

Glioma

Emory UniversityNCT05310448

~$10 – $750

Actual pay is set by the research site.

Idiopathic Pulmonary FibrosisInterstitial Lung DiseaseProgressive Pulmonary Fibrosis

An Open-label Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease (TETON-OLE)

Study RIN-PF-302 is designed to evaluate the long-term safety and tolerability of inhaled treprostinil in subjects with idiopathic pulmonary fibrosis or progre…

United TherapeuticsNCT04905693

~$50 – $2,100

Actual pay is set by the research site.

A Phase 1/2, Open-Label, Platform Study to Evaluate Safety and Efficacy of T Cell Engaging Bi/Tri-specific Antibodies in Subjects With MM

Multiple myeloma (MM) is a cancer of the blood's plasma cells. The cancer is typically found in the bones and bone marrow (the spongy tissue inside of the bone…

Multiple Myeloma

~$150 – $4,500

Actual pay is set by the research site.

AbbVieNCT06892522

Phase I Trial of 5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in Patients With Advanced Solid Tumors

Background: Blood, tissue, and tumor cells contain genes. Genes are made up of DNA. DNA is the "instruction book" for each cell. In some people with cancer, t…

NeoplasmsSolid Tumors

National Cancer Institute (NCI)NCT03366116

~$150 – $2,700

Actual pay is set by the research site.

Diabetes Mellitus, Type 2

Efficacy and Safety of Co-administered Cagrilintide and Semaglutide (CagriSema) s.c. Once Weekly Versus Placebo in Children and Adolescents With Type 2 Diabetes

The purpose of this clinical study is to look into how well a study medicine called CagriSema helps children and adolescents living with diabetes lower their b…

Novo Nordisk A/SNCT07282613

~$50 – $2,250

Actual pay is set by the research site.

A Phase 3 Open-label Extension Study to Investigate the Long-term Safety and Efficacy of Orally Administered NNZ-2591 in Pediatric Participants With Phelan-McDermid Syndrome

This Phase 3, open-label extension, multicenter study will evaluate long-term safety, tolerability and efficacy of NNZ-2591 in pediatric participants with Phel…

Phelan-McDermid Syndrome

Neuren Pharmaceuticals LimitedNCT07593391

~$50 – $2,100

Actual pay is set by the research site.

Observational

REACH Study: Galleri® in the Medicare Population.

This multi-center comparative prospective cohort study is designed to assess the real world clinical impact, including safety and test performance, of Galleri®…

Cancer